These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 23427886)

  • 1. A vaccine to prevent epidemic meningitis in Africa.
    Viviani S
    Lancet Infect Dis; 2013 Mar; 13(3):195-6. PubMed ID: 23427886
    [No Abstract]   [Full Text] [Related]  

  • 2. Serogroup A meningococcal conjugate vaccination in Burkina Faso: analysis of national surveillance data.
    Novak RT; Kambou JL; Diomandé FV; Tarbangdo TF; Ouédraogo-Traoré R; Sangaré L; Lingani C; Martin SW; Hatcher C; Mayer LW; Laforce FM; Avokey F; Djingarey MH; Messonnier NE; Tiendrébéogo SR; Clark TA
    Lancet Infect Dis; 2012 Oct; 12(10):757-64. PubMed ID: 22818241
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of a group A meningococcal conjugate vaccine, MenAfriVac(TM).
    Frasch CE; Preziosi MP; LaForce FM
    Hum Vaccin Immunother; 2012 Jun; 8(6):715-24. PubMed ID: 22495119
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serogroup A meningococcal conjugate (PsA-TT) vaccine coverage and measles vaccine coverage in Burkina Faso--implications for introduction of PsA-TT into the Expanded Programme on Immunization.
    Meyer SA; Kambou JL; Cohn A; Goodson JL; Flannery B; Medah I; Messonnier N; Novak R; Diomande F; Djingarey MH; Clark TA; Yameogo I; Fall A; Wannemuehler K
    Vaccine; 2015 Mar; 33(12):1492-8. PubMed ID: 25636915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccine introduction. The beginning of the end for Africa's devastating meningitis outbreaks?
    Roberts L
    Science; 2010 Dec; 330(6010):1466-7. PubMed ID: 21148362
    [No Abstract]   [Full Text] [Related]  

  • 6. Meningococcal meningitis in sub-Saharan Africa: the case for mass and routine vaccination with available polysaccharide vaccines.
    Robbins JB; Schneerson R; Gotschlich EC; Mohammed I; Nasidi A; Chippaux JP; Bernardino L; Maiga MA
    Bull World Health Organ; 2003; 81(10):745-50; discussion 751-5. PubMed ID: 14758435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serogroup A meningococcal conjugate vaccine coverage after the first national mass immunization campaign-Burkina Faso, 2011.
    Centers for Disease Control and Prevention (CDC)
    MMWR Morb Mortal Wkly Rep; 2012 Dec; 61(50):1022-4. PubMed ID: 23254256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Meningococcal disease control in countries of the African meningitis belt, 2013.
    Wkly Epidemiol Rec; 2014 May; 89(20):206-14. PubMed ID: 24864346
    [No Abstract]   [Full Text] [Related]  

  • 9. Meningococcal serogroup W135 in the African meningitis belt: epidemiology, immunity and vaccines.
    Mueller JE; Borrow R; Gessner BD
    Expert Rev Vaccines; 2006 Jun; 5(3):319-36. PubMed ID: 16827617
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronicle of an outbreak foretold: meningococcal meningitis W135 in Burkina Faso.
    Decosas J; Koama JB
    Lancet Infect Dis; 2002 Dec; 2(12):763-5. PubMed ID: 12467693
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Meningococcal meningitis epidemics in sub-Saharan Africa and the meningococcal A conjugate vaccine].
    Nicolas P
    Med Sante Trop; 2012; 22(3):246-58. PubMed ID: 23186941
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Costs and impact of meningitis epidemics for the public health system in Burkina Faso.
    Colombini A; Badolo O; Gessner BD; Jaillard P; Seini E; Da Silva A
    Vaccine; 2011 Jul; 29(33):5474-80. PubMed ID: 21641952
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antipneumococcal seroprevalence and pneumococcal carriage during a meningococcal epidemic in Burkina Faso, 2006.
    Yaro S; Njanpop-Lafourcade BM; Drabo A; Idohou RS; Kroman SS; Sanou O; Traoré Y; Sangaré L; Diagbouga SP; Koeck JL; Borrow R; Gessner BD; Mueller JE
    J Infect Dis; 2014 Apr; 209(8):1241-50. PubMed ID: 24277740
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Vaccine offers meningitis hope.
    Butler D
    Nature; 2010 Nov; 468(7321):143. PubMed ID: 21068797
    [No Abstract]   [Full Text] [Related]  

  • 15. The Meningitis Vaccine Project.
    LaForce FM; Konde K; Viviani S; Préziosi MP
    Vaccine; 2007 Sep; 25 Suppl 1():A97-100. PubMed ID: 17521780
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study of the immunization coverage determinants of vaccination campaign against meningococcal A meningitis in Burkina Faso].
    Ouatara S; Faye A; Leye MM; Niang K; Tal-Dia A
    Rev Epidemiol Sante Publique; 2015 Dec; 63(6):347-53. PubMed ID: 26547670
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccination against meningococcal meningitis outside the meningitis belt.
    Thapa SD; Koirala KD
    Lancet Infect Dis; 2011 Jun; 11(6):427. PubMed ID: 21616455
    [No Abstract]   [Full Text] [Related]  

  • 18. Emergence of serogroup X meningococcal disease in Africa: need for a vaccine.
    Xie O; Pollard AJ; Mueller JE; Norheim G
    Vaccine; 2013 Jun; 31(27):2852-61. PubMed ID: 23623866
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Meningococcal meningitis: vaccination outbreak response and epidemiological changes in the African meningitis belt.
    Carod Artal FJ
    Int Health; 2015 Jul; 7(4):226-7. PubMed ID: 25878213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Adverse events following immunization during mass vaccination campaigns at first introduction of a meningococcal A conjugate vaccine in Burkina Faso, 2010.
    Ouandaogo CR; Yaméogo TM; Diomandé FV; Sawadogo C; Ouédraogo B; Ouédraogo-Traoré R; Pezzoli L; Djingarey MH; Mbakuliyemo N; Zuber PL
    Vaccine; 2012 May; 30 Suppl 2():B46-51. PubMed ID: 22230584
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.